newsfilter
← Latest News
GlobeNewswire·

MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • MediWound announced third-quarter 2026 revenue of $3.6 million & noted that the full-year 2026 outlook depends on ongoing U.S. government funding discussions.
  • The EscharEx Phase III VALUE trial enrollment is on track to complete, including interim reassessment, by the end of the first quarter of 2027.
  • The independent Data and Safety Monitoring Board found no safety concerns in the VALUE trial & recommended continuing as planned.
  • NexoBrid reported its strongest quarter since launch with record ordering from burn centers, while BARDA procurement began in Q3 2026.
  • The U.S. Department of War awarded MediWound an additional $3.3 million to develop a room-temperature-stable NexoBrid formulation for battlefield use.
  • MediWound secured $17.25 million in gross proceeds from an underwritten public offering completed in November 2026.
  • An expanded NexoBrid manufacturing facility is expected to be modified by Q4 2026, with commercial supply anticipated in the second half of 2027.
  • Q3 2026 operating loss was $8.5 million & net loss was $6.0 million, driven by lower development service revenue & increased R&D investment.
  • Cash & equivalents totaled $28.4 million as of September 30, 2026, following a cash burn of $28.3 million during the first nine months of the year.
  • NexoBrid manufacturing facility successfully passed FDA & EMA inspections, extending GMP certification for two additional years.
  • MediWound management will host a conference call on November 12, 2026, at 8:30 a.m. Eastern Time to discuss results & future milestones.
Company
MediWound Ltd.
Keywords
Nasdaq:MDWD, MediWound Ltd., CONFERENCE CALL, financial, WEBCAST, EARNINGS, PHARMACEUTICALS